Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | March 26, 2013 |
| Target | Arcion Therapeutics - Topical Clonidine Gel |
| Sector | Life Science |
| Buyer(s) | BioDelivery |
| Sellers(s) | Arcion Therapeutics |
| Deal Type | Divestiture |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1997 |
| Sector | Life Science |
| Employees | 176 |
| Revenue | 156M USD (2020) |
BioDelivery is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BioDelivery was formed in 1997 and is based in Raleigh, North Carolina.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2013 | 1 of 1 |
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain; ARC-4558 (topical clonidine gel) for PDN and ARC-2022 (high potency lidocaine gel) for PHN.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2013 | 1 of 1 |
